Profile data is unavailable for this security.
About the company
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
- Revenue in USD (TTM)33.25m
- Net income in USD-23.09m
- Incorporated2015
- Employees85.00
- LocationBiofrontera Inc120 Presidential Way,, Suite 330WOBURN 01801United StatesUSA
- Phone+1 (781) 245-1325
- Fax+1 (302) 655-5049
- Websitehttps://www.biofrontera-us.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProtoKinetix, Inc. | 0.00 | -400.47k | 5.01m | 0.00 | -- | 12.63 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| GB Sciences Inc | 0.00 | -4.03m | 5.08m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
| Stemtech Corp | 4.64m | -4.08m | 5.09m | 45.00 | -- | -- | -- | 1.10 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
| Mystic Holdings Inc | -100.00bn | -100.00bn | 5.10m | 79.00 | -- | 0.2093 | -- | -- | -- | -- | -- | 0.2155 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2228 | -- | 0.1849 | -- | 199.82 | -- | 34.32 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 5.11m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Helix BioMedix, Inc. | 2.07m | -2.58m | 5.23m | 8.00 | -- | 3.35 | -- | 2.53 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
| Biofrontera Inc | 33.25m | -23.09m | 5.24m | 85.00 | -- | -- | -- | 0.1577 | -12.47 | -12.47 | 16.84 | -0.3627 | 0.9995 | 2.50 | 5.75 | 391,200.00 | -69.40 | -- | -144.06 | -- | 48.99 | -- | -69.44 | -- | 0.944 | -3.55 | 4.63 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.69m | 5.26m | 3.00 | -- | -- | -- | -- | -2.38 | -2.38 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -118.45 | -104.18 | -130.17 | -111.05 | -- | -- | -- | -- | -- | -1,253.20 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.32m | 4.00 | -- | 0.5354 | -- | 0.664 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
| AccuStem Sciences Inc | 0.00 | -1.74m | 5.33m | 3.00 | -- | -- | -- | -- | -0.1537 | -0.1537 | 0.00 | -0.2309 | 0.00 | -- | -- | 0.00 | -1,168.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 45.26 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 5.34m | 3.00 | 3.62 | -- | 210.54 | 18.99 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Azitra Inc | 572.70k | -12.40m | 5.39m | 10.00 | -- | 1.25 | -- | 9.41 | -2.87 | -2.87 | 0.0492 | 0.1501 | 0.0977 | -- | 11.54 | 57,270.00 | -200.61 | -- | -287.43 | -- | -- | -- | -2,053.34 | -- | -- | -129.02 | 0.0085 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Ainos Inc | 93.68k | -14.56m | 5.40m | 46.00 | -- | 0.233 | -- | 57.69 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| HST Global Inc | 0.00 | -146.22k | 5.46m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
Data as of Jun 03 2024. Currency figures normalised to Biofrontera Inc's reporting currency: US Dollar USD
22.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rosalind Advisors, Inc.as of 13 May 2024 | 504.26k | 9.91% |
| AIGH Capital Management LLCas of 15 Apr 2024 | 501.43k | 9.85% |
| Matejka & Partner Asset Management GmbHas of 29 Dec 2023 | 43.00k | 0.85% |
| Scotia Capital, Inc. (Broker)as of 31 Mar 2024 | 40.00k | 0.79% |
| XTX Markets LLCas of 31 Mar 2024 | 12.19k | 0.24% |
| HRT Financial LLCas of 31 Mar 2024 | 10.64k | 0.21% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 10.22k | 0.20% |
| amandea Verm�gensverwaltung AGas of 31 Dec 2022 | 10.00k | 0.20% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.62k | 0.09% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.91k | 0.04% |
More ▼
Data from 29 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
